Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
BACKGROUND Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the v...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2021
|
| _version_ | 1797072621415694336 |
|---|---|
| author | Heath, PT Galiza, EP Baxter, DN Boffito, M Browne, D Burns, F Chadwick, DR Clark, R Cosgrove, C Galloway, J Goodman, AL Heer, A Higham, A Iyengar, S Jamal, A Jeanes, C Kalra, PA Kyriakidou, C McAuley, DF Meyrick, A Minassian, AM Minton, J Moore, P Munsoor, I Nicholls, H Osanlou, O Packham, J Pretswell, CH San Francisco Ramos, A Saralaya, D Sheridan, RP Smith, R Soiza, RL Swift, PA Thomson, EC Turner, J Viljoen, ME Albert, G Cho, I Dubovsky, F Glenn, G Rivers, J Robertson, A Smith, K Toback, S |
| author2 | 2019nCoV-302 Study Group |
| author_facet | 2019nCoV-302 Study Group Heath, PT Galiza, EP Baxter, DN Boffito, M Browne, D Burns, F Chadwick, DR Clark, R Cosgrove, C Galloway, J Goodman, AL Heer, A Higham, A Iyengar, S Jamal, A Jeanes, C Kalra, PA Kyriakidou, C McAuley, DF Meyrick, A Minassian, AM Minton, J Moore, P Munsoor, I Nicholls, H Osanlou, O Packham, J Pretswell, CH San Francisco Ramos, A Saralaya, D Sheridan, RP Smith, R Soiza, RL Swift, PA Thomson, EC Turner, J Viljoen, ME Albert, G Cho, I Dubovsky, F Glenn, G Rivers, J Robertson, A Smith, K Toback, S |
| author_sort | Heath, PT |
| collection | OXFORD |
| description | BACKGROUND
Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population.
METHODS
In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to receive two intramuscular 5-μg doses of NVX-CoV2373 or placebo administered 21 days apart. The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline.
RESULTS
A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.
CONCLUSIONS
A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. |
| first_indexed | 2024-03-06T23:10:24Z |
| format | Journal article |
| id | oxford-uuid:65431bb2-1852-4010-b812-a1624003cbca |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:10:24Z |
| publishDate | 2021 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:65431bb2-1852-4010-b812-a1624003cbca2022-03-26T18:24:31ZSafety and efficacy of NVX-CoV2373 Covid-19 vaccineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:65431bb2-1852-4010-b812-a1624003cbcaEnglishSymplectic ElementsMassachusetts Medical Society2021Heath, PTGaliza, EPBaxter, DNBoffito, MBrowne, DBurns, FChadwick, DRClark, RCosgrove, CGalloway, JGoodman, ALHeer, AHigham, AIyengar, SJamal, AJeanes, CKalra, PAKyriakidou, CMcAuley, DFMeyrick, AMinassian, AMMinton, JMoore, PMunsoor, INicholls, HOsanlou, OPackham, JPretswell, CHSan Francisco Ramos, ASaralaya, DSheridan, RPSmith, RSoiza, RLSwift, PAThomson, ECTurner, JViljoen, MEAlbert, GCho, IDubovsky, FGlenn, GRivers, JRobertson, ASmith, KToback, S2019nCoV-302 Study GroupBACKGROUND Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population. METHODS In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to receive two intramuscular 5-μg doses of NVX-CoV2373 or placebo administered 21 days apart. The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline. RESULTS A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups. CONCLUSIONS A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. |
| spellingShingle | Heath, PT Galiza, EP Baxter, DN Boffito, M Browne, D Burns, F Chadwick, DR Clark, R Cosgrove, C Galloway, J Goodman, AL Heer, A Higham, A Iyengar, S Jamal, A Jeanes, C Kalra, PA Kyriakidou, C McAuley, DF Meyrick, A Minassian, AM Minton, J Moore, P Munsoor, I Nicholls, H Osanlou, O Packham, J Pretswell, CH San Francisco Ramos, A Saralaya, D Sheridan, RP Smith, R Soiza, RL Swift, PA Thomson, EC Turner, J Viljoen, ME Albert, G Cho, I Dubovsky, F Glenn, G Rivers, J Robertson, A Smith, K Toback, S Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title | Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title_full | Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title_fullStr | Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title_full_unstemmed | Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title_short | Safety and efficacy of NVX-CoV2373 Covid-19 vaccine |
| title_sort | safety and efficacy of nvx cov2373 covid 19 vaccine |
| work_keys_str_mv | AT heathpt safetyandefficacyofnvxcov2373covid19vaccine AT galizaep safetyandefficacyofnvxcov2373covid19vaccine AT baxterdn safetyandefficacyofnvxcov2373covid19vaccine AT boffitom safetyandefficacyofnvxcov2373covid19vaccine AT browned safetyandefficacyofnvxcov2373covid19vaccine AT burnsf safetyandefficacyofnvxcov2373covid19vaccine AT chadwickdr safetyandefficacyofnvxcov2373covid19vaccine AT clarkr safetyandefficacyofnvxcov2373covid19vaccine AT cosgrovec safetyandefficacyofnvxcov2373covid19vaccine AT gallowayj safetyandefficacyofnvxcov2373covid19vaccine AT goodmanal safetyandefficacyofnvxcov2373covid19vaccine AT heera safetyandefficacyofnvxcov2373covid19vaccine AT highama safetyandefficacyofnvxcov2373covid19vaccine AT iyengars safetyandefficacyofnvxcov2373covid19vaccine AT jamala safetyandefficacyofnvxcov2373covid19vaccine AT jeanesc safetyandefficacyofnvxcov2373covid19vaccine AT kalrapa safetyandefficacyofnvxcov2373covid19vaccine AT kyriakidouc safetyandefficacyofnvxcov2373covid19vaccine AT mcauleydf safetyandefficacyofnvxcov2373covid19vaccine AT meyricka safetyandefficacyofnvxcov2373covid19vaccine AT minassianam safetyandefficacyofnvxcov2373covid19vaccine AT mintonj safetyandefficacyofnvxcov2373covid19vaccine AT moorep safetyandefficacyofnvxcov2373covid19vaccine AT munsoori safetyandefficacyofnvxcov2373covid19vaccine AT nichollsh safetyandefficacyofnvxcov2373covid19vaccine AT osanlouo safetyandefficacyofnvxcov2373covid19vaccine AT packhamj safetyandefficacyofnvxcov2373covid19vaccine AT pretswellch safetyandefficacyofnvxcov2373covid19vaccine AT sanfranciscoramosa safetyandefficacyofnvxcov2373covid19vaccine AT saralayad safetyandefficacyofnvxcov2373covid19vaccine AT sheridanrp safetyandefficacyofnvxcov2373covid19vaccine AT smithr safetyandefficacyofnvxcov2373covid19vaccine AT soizarl safetyandefficacyofnvxcov2373covid19vaccine AT swiftpa safetyandefficacyofnvxcov2373covid19vaccine AT thomsonec safetyandefficacyofnvxcov2373covid19vaccine AT turnerj safetyandefficacyofnvxcov2373covid19vaccine AT viljoenme safetyandefficacyofnvxcov2373covid19vaccine AT albertg safetyandefficacyofnvxcov2373covid19vaccine AT choi safetyandefficacyofnvxcov2373covid19vaccine AT dubovskyf safetyandefficacyofnvxcov2373covid19vaccine AT glenng safetyandefficacyofnvxcov2373covid19vaccine AT riversj safetyandefficacyofnvxcov2373covid19vaccine AT robertsona safetyandefficacyofnvxcov2373covid19vaccine AT smithk safetyandefficacyofnvxcov2373covid19vaccine AT tobacks safetyandefficacyofnvxcov2373covid19vaccine |